Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Tennis legend Novak Djokovic has opened up about a longstanding health issue he has been dealing with for years.

At the Cincinnati Open, the Serbian, who holds the all-time men's record of 428 weeks as world No. 1 in singles, struggled physically throughout his second-round match.

The 39-year-old was seen crouching on all fours between points, required a medical timeout and appeared to vomit into towels as extreme heat and humidity took a toll.

The 24-time Grand Slam champion suffered a surprising second-round defeat, losing to Argentina's Thiago Agustín Tirante 2-6, 6-4, 6-4.

What Health Issue Does Novak Djokovic Have?

Following the defeat, Djokovic revealed that he has been dealing with a longstanding health condition that becomes particularly difficult to manage in hot and humid conditions.

"It's because of a health issue I have," Djokovic told reporters after the match. "I've been dealing with it for many years now. It causes me a lot of problems, especially when there's a lot of humidity and heat."

Djokovic said he had anticipated difficult conditions in Cincinnati, but the combination of heat, humidity, nerves and other factors ultimately made the situation worse during his match against Tirante.

His physical struggles also raised questions about his future at the Cincinnati Open. Asked whether he planned to return to the tournament in 2027, Djokovic gave an uncertain response.

"I certainly hope so, but unfortunately, at this point it seems more likely that I won't. However, we'll see what the future holds."

Novak Djokovic's Previous Health Issues and Injuries

Djokovic has dealt with several injuries and health challenges throughout his career.

• Respiratory issues: Before 2010, Djokovic faced heat exhaustion, breathing difficulties and physical collapses. He later changed his diet after identifying gluten and dairy intolerance.

• Elbow injury: Chronic right elbow problems led to surgery in 2018.

• Abdominal tear: He played through an abdominal tear to win the 2021 Australian Open.

• Hamstring injury: He battled a left hamstring injury during his 2023 Australian Open title run.

• Knee injury: A torn meniscus forced him to withdraw from the 2024 French Open.

Djokovic on the Physical Demands of Ageing

In 2023, Djokovic acknowledged that his body was beginning to feel the effects of a long career, although he still felt he had fuel left in the tank.

"I am being completely honest with you guys. I have asked this question also, but it's not like I think about it all the time.

The desire is still there, but things can change quickly – I am 36, I've been a pro for 20 years."

He said he did not view age as a decisive factor, instead focusing on his overall physical condition and whether he continued to enjoy playing.

Age can affect tennis performance through changes such as reduced muscle mass, slower recovery and lower aerobic capacity, which can also increase injury risk. However, modern sports science and tactics can help players remain competitive as they age.

Research suggests that people who regularly play tennis may add nearly 10 years to their lives, potentially outperforming the longevity gains associated with several other sports.

"Tennis is a sport that is unique because people of all ages play it, from age two to 92 or older, and that makes it accessible to a lot of people," Dr. Melissa Leber, director of emergency department sports medicine at Mount Sinai Health System, told the New York Post.

The Ebola outbreak in the Democratic Republic of Congo (DRC) has become the deadliest one in the country’s history, with the death toll reaching 2,325, according to the latest reports.

The number has now surpassed the 2,299 deaths recorded during the 2018–2020 Ebola outbreak, which had previously been the country’s worst. The current outbreak has also become the largest in the DRC by number of confirmed cases, with 4,945 infections recorded so far.

The latest figures indicate that the outbreak has reached another grim milestone just three months after it was officially declared on May 15.

Ebola Is Spreading Rapidly

The DRC’s National Public Health Institute reported 101 new confirmed cases in the 24 hours leading up to its latest update, highlighting how quickly transmission is continuing.

The outbreak was first detected in Ituri province, but the virus has since spread to six provinces, including North Kivu, South Kivu, Haut-Uele, Tshopo and Bas-Uele. More than 3,400 cases have been reported in Ituri alone.

The United Nations has described the outbreak as the fastest-growing Ebola epidemic on record.

“Ebola is winning in the Democratic Republic of the Congo. We cannot let the virus outrun our response,” UN humanitarian chief Tom Fletcher said, calling for “speed, scale, and solidarity” before the outbreak gets even further ahead of containment efforts.

Also read: Ebola Outbreak Is Claiming 1 Life Every 30 Minutes In DR Congo: UN Humanitarian Official

The Most Deadly Outbreak

One of the biggest reasons behind rapid transmission is that people are still being diagnosed too late. Thomas Parisch, a public health specialist with Médecins Sans Frontières, said that normally the proportion of people dying should fall as outbreaks progress because contact tracing improves and patients receive treatment earlier.

“Instead, we're still seeing many cases detected very late,” he said, with some infections only being identified after patients have died in their communities.

The case-fatality ratio has climbed from around 20% in early June to approximately 46%, according to Reuters.

That does not mean the virus itself has become more lethal. Rather, the increase is a warning that many patients are reaching healthcare facilities too late for treatment to be effective.

Also read: Ebola 2026 Outbreak Spreading Faster Than Any Before, On Track To Become Deadliest: WHO Chief

No Approved Vaccine

The current outbreak is being caused by the Bundibugyo species of Ebola, a relatively rare strain.

Unlike the Zaire species responsible for several previous major Ebola outbreaks, Bundibugyo currently has no approved vaccine or specific treatment. WHO says experimental vaccines and treatments are being investigated, but they remain under evaluation.

This makes early diagnosis, isolation, contact tracing and supportive medical care particularly important.

The outbreak is also unfolding in an extremely difficult environment. Conflict, population movement, weak healthcare infrastructure, misinformation and shortages of resources are making it harder for health teams to identify and isolate infections quickly. Health workers have also demonstrated strikes due to unpaid wages.

Also read: Amid Rapidly Expanding Ebola Outbreak, DR Congo Is Seeing An Alarming Increase In Maternal Deaths; Here's Why

Efforts Towards Containing The Outbreak

Despite the challenges, WHO chief Dr Tedros Adhanom Ghebreyesus said significant progress has been made towards containing and eradicating the virus. It includes:

• More than 21,000 community health workers have been trained.
• Treatment centres, safe burial teams, laboratories and community engagement teams are operating across the affected provinces, reaching hundreds of thousands of people.
• A total of 886 patients have recovered, even without specific therapeutics and vaccines, which are progressing through trials.
• For the first time, two vaccines specifically designed against Bundibugyo virus have entered Phase 1 safety trials in humans.
• Two new animal studies of a vaccine against Zaire ebolavirus — the more common species — have shown promising evidence of cross-protection in animals, Tedros said.

In an early trial, scientists are testing the possibility if a vaccine could intercept pancreatic cancer, one of the deadliest cancers in the US, at an early stage and prevent it from becoming invasive.

The trial involves people who were considered at high risk of pancreatic cancer and already had small abnormalities, like cysts, in their pancreas.

The experimental vaccine, called mKRAS-VAX, is designed to train the immune system to recognise mutated KRAS proteins, which are found in most pancreatic ductal adenocarcinomas, the most common type of pancreatic cancer.

The findings, published in Cancer Discovery, offer an intriguing new approach in which instead of waiting for pancreatic cancer to appear and then treating it, researchers are attempting to intercept the disease at its earliest stages.

How Does The Vaccine Work?

Also read: UK Set To Implement Stricter Protocol For Prostate Cancer Testing; Who Is Eligible To Get Tested?

Pancreatic cancer often develops gradually from precursor lesions. Some of these lesions can contain mutations in the KRAS gene, which can drive the development of the disease.

The mKRAS-VAX vaccine contains synthetic peptides targeting six common KRAS mutations. The goal is to teach T cells to recognise cells carrying these abnormal proteins and destroy them before they progress into cancer.

Unlike traditional vaccines against infections, this is a therapeutic cancer vaccine, meaning it is designed to stimulate the patient's immune system against targets related to cancer.

Findings From The Early Trial

Also read: Following A Western Diet? Changes In Your Gut Bacteria Could Increase Colon Cancer Risk

The Phase 1 study involved 20 people who had either a family history or genetic predisposition to pancreatic cancer and had a pancreatic abnormality detected on imaging.

The vaccine produced mutant-KRAS-specific T-cell responses in 18 of the 20 participants, or 90%. These immune responses persisted for as long as two years. Researchers also saw an intriguing change in pancreatic cysts.

At a median follow-up of 16.5 months, 37.5% of participants experienced cyst reduction or complete resolution. Among a comparable group of unvaccinated people, the figure was 6.8%.

None of the vaccinated participants had developed pancreatic ductal adenocarcinoma during the study follow-up. However, this does not prove that the vaccine prevents pancreatic cancer.

The study was small, early-stage and primarily designed to examine safety and whether the vaccine could generate an immune response.

“We are very excited about these results,” pancreatic cancer vaccine researcher Elizabeth Jaffee said.

More About Pancreatic Cysts

The researchers are interested in whether vaccination could intervene during this window, before malignant cells are formed.

That is particularly significant because pancreatic cancer is notoriously difficult to detect early and remains one of the deadliest cancers.

The long-term ambition is to develop a vaccine to prevent pancreatic cancer but researchers are not there yet.

Jaffee described the field as “nascent” and said she is “cautiously optimistic,” while emphasising that these small Phase 1 studies are not designed to establish whether the vaccines improve survival or prevent cancer.

Larger Phase 2 studies will be needed to determine whether the early immune responses translate into meaningful clinical benefits.